JP5670608B2 - 髄鞘再形成を誘導する能力を有するヒトＩｇＭ抗体、および、特に中枢神経系における、その診断使用及び治療使用 - Google Patents

髄鞘再形成を誘導する能力を有するヒトＩｇＭ抗体、および、特に中枢神経系における、その診断使用及び治療使用 Download PDF

Info

Publication number
JP5670608B2
JP5670608B2 JP2001582396A JP2001582396A JP5670608B2 JP 5670608 B2 JP5670608 B2 JP 5670608B2 JP 2001582396 A JP2001582396 A JP 2001582396A JP 2001582396 A JP2001582396 A JP 2001582396A JP 5670608 B2 JP5670608 B2 JP 5670608B2
Authority
JP
Japan
Prior art keywords
cells
antibody
remyelination
human
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001582396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004516807A5 (zh
JP2004516807A (ja
Inventor
モッセズ ロドリゲス
モッセズ ロドリゲス
デイヴィッド ジェイ ミラー
デイヴィッド ジェイ ミラー
ラリー アール ピース
ラリー アール ピース
Original Assignee
メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ
メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ, メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ filed Critical メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ
Publication of JP2004516807A publication Critical patent/JP2004516807A/ja
Publication of JP2004516807A5 publication Critical patent/JP2004516807A5/ja
Application granted granted Critical
Publication of JP5670608B2 publication Critical patent/JP5670608B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2001582396A 2000-05-10 2000-05-30 髄鞘再形成を誘導する能力を有するヒトＩｇＭ抗体、および、特に中枢神経系における、その診断使用及び治療使用 Expired - Lifetime JP5670608B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56835100A 2000-05-10 2000-05-10
US09/568,351 2000-05-10
PCT/US2000/014902 WO2001085797A1 (en) 2000-05-10 2000-05-30 Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012168953A Division JP5795753B2 (ja) 2000-05-10 2012-07-30 髄鞘再形成を誘導する能力を有するヒトＩｇＭ抗体、および、特に中枢神経系における、その診断使用及び治療使用

Publications (3)

Publication Number Publication Date
JP2004516807A JP2004516807A (ja) 2004-06-10
JP2004516807A5 JP2004516807A5 (zh) 2007-07-12
JP5670608B2 true JP5670608B2 (ja) 2015-02-18

Family

ID=24270921

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001582396A Expired - Lifetime JP5670608B2 (ja) 2000-05-10 2000-05-30 髄鞘再形成を誘導する能力を有するヒトＩｇＭ抗体、および、特に中枢神経系における、その診断使用及び治療使用
JP2012168953A Expired - Lifetime JP5795753B2 (ja) 2000-05-10 2012-07-30 髄鞘再形成を誘導する能力を有するヒトＩｇＭ抗体、および、特に中枢神経系における、その診断使用及び治療使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012168953A Expired - Lifetime JP5795753B2 (ja) 2000-05-10 2012-07-30 髄鞘再形成を誘導する能力を有するヒトＩｇＭ抗体、および、特に中枢神経系における、その診断使用及び治療使用

Country Status (11)

Country Link
EP (3) EP2287191B1 (zh)
JP (2) JP5670608B2 (zh)
AT (1) ATE536375T1 (zh)
AU (2) AU6197800A (zh)
BR (1) BR0015875A (zh)
CA (2) CA2409515C (zh)
ES (3) ES2609494T3 (zh)
HK (1) HK1154604A1 (zh)
IL (3) IL152738A0 (zh)
MX (2) MXPA02011163A (zh)
WO (1) WO2001085797A1 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
CA2469393C (en) 2001-12-04 2010-05-25 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
MXPA04008267A (es) 2002-02-25 2004-11-10 Elan Pharm Inc Administracion de agentes para el tratamiento de la inflamacion.
MXPA05007843A (es) * 2003-01-24 2005-10-18 Elan Pharm Inc Composicion y tratamiento de enfermedades desmielinizantes y paralisis por administracion de agentes de remielinizantes.
AU2004247021A1 (en) 2003-05-16 2004-12-23 Acorda Therapeutics Compositions and methods including a recombinant human MAB that promotes CNS remyelination
ATE469920T1 (de) * 2003-05-23 2010-06-15 Crucell Holland Bv Herstellung von rekombinanten igm in den per.c6 zellen
US7501119B2 (en) 2004-06-30 2009-03-10 Mayo Foundation For Medical Education And Research Methods and molecules for modulating an immune response
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
CN103275216B (zh) 2007-03-12 2015-05-06 艾斯巴技术-诺华有限责任公司 单链抗体的基于序列的工程改造和最优化
EP2164961B1 (en) 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
CN102838673B (zh) * 2007-06-25 2016-05-11 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
WO2010046876A1 (en) * 2008-10-22 2010-04-29 Universidade De Coimbra Method for the Functional identification of SVZ-derived oligodendrocytes based on selective resuponse to thrombin and utilization thereof
WO2012045324A1 (en) * 2010-10-07 2012-04-12 Mediagnost Gesellschaft Fur Forschung Und Herstellung Von Diagnostika Gmbh Method for detecting a parkinson's disease and test system
NZ609607A (en) 2010-10-19 2014-12-24 Mayo Foundation Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
WO2012149024A2 (en) 2011-04-28 2012-11-01 Mayo Foundation For Medical Education And Research Dna aptamers for promoting remyelination
MX369444B (es) * 2012-02-29 2019-11-08 Baxalta Inc REMIELINIZACION DE NERVIOS PERIFERICOS ESTIMULADA POR IgG.
JP6162219B2 (ja) 2012-04-17 2017-07-12 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 脳卒中および虚血または虚血状態において使用するためのヒト抗体およびその特異的結合配列
EP3215190A4 (en) 2014-11-07 2018-10-31 Mayo Foundation for Medical Education and Research Treatment of neonatal hypoxia including impairments or effects thereof
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
RU2736070C1 (ru) * 2019-09-30 2020-11-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Тест-модель для исследования действия лекарственных препаратов, препятствующих демиелинизации, способ ее получения и применения

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4451570A (en) 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
AU658836B2 (en) 1990-09-25 1995-05-04 Xenova Research Limited Viral defective vaccine produced by transcomplementing cell line
JPH08507784A (ja) 1993-03-19 1996-08-20 キャンタブ ファーマシューティカルズ リサーチ リミティド ウイルス・ワクチン
AU7477394A (en) 1993-07-30 1995-03-27 University Of Medicine And Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
EP0753069A1 (en) 1994-04-15 1997-01-15 Targeted Genetics Corporation Gene delivery fusion proteins
US5591629A (en) * 1994-04-29 1997-01-07 Mayo Foundation For Medical Education & Research Monoclonal antibodies which promote central nervous system remyelination

Also Published As

Publication number Publication date
JP5795753B2 (ja) 2015-10-14
EP2287191B1 (en) 2016-10-12
HK1154604A1 (zh) 2012-04-27
EP2287191A3 (en) 2011-03-30
ES2376725T3 (es) 2012-03-16
MX347175B (es) 2017-04-17
ES2531552T3 (es) 2015-03-17
CA2409515A1 (en) 2001-11-15
CA2901451A1 (en) 2001-11-15
EP2287190A2 (en) 2011-02-23
EP2287191A2 (en) 2011-02-23
IL212686A0 (en) 2011-07-31
IL152738A0 (en) 2003-06-24
EP2287190B1 (en) 2014-12-17
WO2001085797A1 (en) 2001-11-15
CA2901451C (en) 2020-04-07
ES2609494T3 (es) 2017-04-20
IL212686A (en) 2014-07-31
AU6197800A (en) 2001-11-20
JP2004516807A (ja) 2004-06-10
CA2409515C (en) 2015-11-24
BR0015875A (pt) 2003-06-24
ATE536375T1 (de) 2011-12-15
EP1294770A1 (en) 2003-03-26
EP2287190A3 (en) 2011-03-23
IL152738A (en) 2011-06-30
JP2013059318A (ja) 2013-04-04
AU2000261978B2 (en) 2006-07-06
MXPA02011163A (es) 2004-08-19
EP1294770B1 (en) 2011-12-07

Similar Documents

Publication Publication Date Title
JP5795753B2 (ja) 髄鞘再形成を誘導する能力を有するヒトＩｇＭ抗体、および、特に中枢神経系における、その診断使用及び治療使用
US10351620B2 (en) Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
AU2000261978A1 (en) Human IgM antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US8501705B2 (en) Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
ES2296986T3 (es) Anticuerpos recombinantes asociados a gancliosidos y el uso de los mismos en la diagnosis y el tratamiento de tumores.
IL232864A (en) Antibodies that neutralize human cytomegalovirus gh site 1 protein and their uses
BRPI0613387A2 (pt) anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
BRPI0910622A2 (pt) ANTICORPOS CONTRA FcRn E USOS DOS MESMOS
EA020508B1 (ru) ВЫДЕЛЕННЫЕ АНТИТЕЛА К Sp35 И ИХ ПРИМЕНЕНИЕ
US20040214761A1 (en) Method for treating multiple myeloma
US7923010B2 (en) Methods and materials for treating autoimmune diseases and conditions
JP2007505157A (ja) ＣＮＳ髄鞘再形成を促進する組換えヒトｍＡｂを含む組成物および方法
US20070128672A1 (en) Anti-p53 Antibodies
JP2023530255A (ja) 末梢神経再生を促進するためのｃｘｃｌ１３結合分子の使用
JP2022180487A (ja) Ｈｔｌｖ－１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法
Meng Anti-acetylcholine receptor autoantibodies in myasthenia gravis: pathogenicity and specificity related to their structure
Guth The receptor presentation hypothesis and development of lupus-like disease in partial IgH transgene mice
MXPA99008621A (es) Peptidos de union a ctla-4, inmunoterapeuticos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100408

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100708

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110616

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110916

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120914

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120921

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20121116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140926

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141218

R150 Certificate of patent or registration of utility model

Ref document number: 5670608

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term